Hematology-Oncology – Page 3

Structural Differences in Tisa-cel and Axi-cel CAR-T Therapies and Their Impact on CD19 Resistance in B-cell Malignancies

By MedXY 09/01/2026

Distinct CAR architectures in tisa-cel (4-1BB costimulation) and axi-cel (CD28 costimulation) influence mechanisms of resistance through CD19 loss, affecting relapse rates in B-cell malignancies treated with CD19-CAR-T therapies.

Hematology-Oncology news

Decoding Chromosome 5q Deletion: Driving Aneuploidy Evolution and Therapeutic Strategies in Complex Karyotype Myeloid Neoplasms

By MedXY 09/01/2026

Chromosome 5q deletions combined with TP53 mutations drive stepwise aneuploid evolution in complex karyotype AML, unveiling shared transcriptional vulnerabilities exploitable by targeted therapies like BCL2 inhibition with venetoclax.

Hematology-Oncology news

Genetic Risk and Ibrutinib Treatment Outcomes in Early-Stage CLL: Insights from the GCLLSG CLL12 Trial

By MedXY 09/01/2026

The GCLLSG CLL12 trial reveals ibrutinib’s event-free survival benefits in specific genetic subgroups of early-stage CLL, while affirming watch-and-wait as standard for high-risk patients with del(17p) and TP53 mutations.

Hematology-Oncology Neurology news

Recent Mechanical Venous Thrombosis Risk Factors and Their Role in Young-Onset Cryptogenic Ischemic Stroke: New Insights from the SECRETO Study

By MedXY 08/31/2026

This multicenter study reveals that recent mechanical venous thrombosis risk factors markedly increase the risk of cryptogenic ischemic stroke in young adults, especially in those under 40 and with patent foramen ovale, independent of thrombophilic markers.

Hematology-Oncology Neurology news

Recent Mechanical Venous Thrombosis Risk Factors and Their Role in Young-Onset Cryptogenic Ischemic Stroke

By MedXY 08/30/2026

This multicenter study reveals that recent mechanical venous thrombosis risk factors within 14 days significantly increase the risk of cryptogenic ischemic stroke in young adults, notably in those under 40 and with patent foramen ovale, independent of thrombophilia markers.

Hematology-Oncology news Oncology

Cancer Biologics Utilization After Biosimilar Entry and Financial Implications For Payers and Patients

By MedXY 08/30/2026

This study examines the impact of biosimilar introduction on cancer biologics, highlighting reduced costs and market share for originator biologics, benefiting both payers and patients.

Cardiology Hematology-Oncology news

Plasma Biomarkers CPVL and PIGR Predict Anthracycline-Induced Cardiotoxicity in Hematologic Cancer Patients

By MedXY 08/28/2026

Baseline plasma levels of CPVL and PIGR correlate with anthracycline-induced systolic dysfunction, offering potential early biomarkers for cardiotoxicity in hematologic malignancy patients undergoing chemotherapy.

Hematology-Oncology news

Ivosidenib Monotherapy Shows Promise in IDH1 Mutated Myelodysplastic Neoplasm/Syndrome: A Phase 2 Study

By MedXY 08/28/2026

Ivosidenib monotherapy demonstrates substantial efficacy and safety in IDH1 mutated myelodysplastic neoplasm, especially in treatment-naïve high-risk patients, offering a new therapeutic option.

Hematology-Oncology news Pathology & Lab Medicine

Enhancing Prognostic Accuracy in Acute Myeloid Leukemia through DNA Methylation Signatures

By MedXY 08/28/2026

DNA methylation profiling in AML patients reveals epigenetic subtypes that mirror genetic mutations, improving risk stratification and outcome prediction beyond standard genetic markers.

Allergy & Immunology Hematology-Oncology news

Divergent Roles of IL-12p40 and IL-18 in Severe Fibrosing Chronic Graft-versus-Host Disease: Implications for Immunity and Post-Transplant Outcomes

By MedXY 08/28/2026

This study reveals distinct clinical associations of IL-12p40 and IL-18 in severe fibrosing chronic graft-versus-host disease, highlighting their differing impacts on relapse risk, survival, and immune responses post-allogeneic stem cell transplantation.

Hematology-Oncology news Oncology

Navigating the Decision-Making Burden in Cancer Care: Oncologists’ Perspectives and Strategies

By MedXY 08/28/2026

This article explores how oncology clinicians perceive and manage the burden patients face when involved in treatment decisions, highlighting varied clinician approaches to balance patient autonomy with emotional support in shared decision making.

Hematology-Oncology news Pediatrics

Epstein-Barr Virus Reactivation and PTLD in Pediatric Haploidentical HSCT: Incidence, Risks, and Clinical Outcomes

By MedXY 08/28/2026

This study analyzes EBV infection and PTLD incidence in pediatric haploidentical HSCT, identifying prior CAR-T therapy, CMV viremia, and TBI conditioning as significant risk factors, with implications for enhanced monitoring and preemptive treatments.

$Targeting ITK with Soquelitinib: A Promising Phase 1 Trial in Relapsed/Refractory T Cell Lymphomas$

Hematology-Oncology news Oncology

Targeting ITK with Soquelitinib: A Promising Phase 1 Trial in Relapsed/Refractory T Cell Lymphomas

By MedXY 08/28/2026

A phase 1 trial of soquelitinib, a selective ITK inhibitor, showed favorable safety and encouraging efficacy with Th1-skewing immunomodulation in relapsed/refractory peripheral T cell lymphomas, highlighting a novel therapeutic approach.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Distinct Myeloid Landscapes Define Prognostic Niches in Extranodal NK/T-Cell Lymphoma

By MedXY 08/28/2026

Spatial multimodal profiling reveals two macrophage-defined ENKTL subgroups with distinct tumor-myeloid interactions influencing prognosis and potential immunotherapy targets.

Hematology-Oncology news

Discovery of a Novel B-ALL Subtype Defined by IGH::FENDRR Rearrangement and KRAS Mutations With Poor Chemotherapy Response

By MedXY 08/27/2026

A novel B-cell acute lymphoblastic leukemia subtype characterized by IGH::FENDRR rearrangement and KRAS mutations shows distinct molecular features and poor response to standard chemotherapy, highlighting the need for early immunotherapy and targeted interventions.

$Fecal Microbiota Transplantation: A Promising Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease$

Gastroenterology Hematology-Oncology news

Fecal Microbiota Transplantation: A Promising Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

By MedXY 08/27/2026

This retrospective multicenter study evaluates fecal microbiota transplantation (FMT) for steroid-refractory acute graft-versus-host disease (aGvHD), demonstrating a 60.5% response at day 28 and highlighting FMT's potential as a safe and effective treatment option.

Hematology-Oncology news

Immunosenescence as a Key Barrier to CD19 CAR T-Cell Therapy in Chronic Lymphocytic Leukemia

By MedXY 08/27/2026

This article explores how T-cell immunosenescence impairs the efficacy of CD19 CAR T-cell therapy in chronic lymphocytic leukemia, highlighting potential therapeutic strategies to overcome this barrier.

Hematology-Oncology news

TP53-Mutated Clonal Hematopoiesis Drives Pro-Inflammatory Phenotype and Predicts Poor Outcomes After CAR T-Cell Therapy

By MedXY 08/26/2026

TP53-mutant clonal hematopoiesis in CAR T-cell recipients is linked to a pro-inflammatory state, cytopenias, and worse survival, highlighting the importance of tailored monitoring strategies in this high-risk group.

Hematology-Oncology news

Janus Kinase Inhibitors: Transforming Treatment Paradigms in Lymphomas and Immune-Mediated Complications

By MedXY 08/26/2026

Janus kinase inhibitors have emerged as pivotal agents in managing lymphoid malignancies and associated immune complications, offering new therapeutic avenues shaped by molecular insights into the JAK/STAT pathway.

Hematology-Oncology news Oncology

Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis

By MedXY 08/26/2026

The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients.